Quantitative MRI and prostate cancer

Quantitative MRI for Prostate Cancer Detection and Monitoring AI Theater Presentation and RSNA 2021

(SAN DIEGO, Nov. 28, 2021)Cortechs.ai, creators of the first volumetric MRI AI application for clinical use, NeuroQuant, will be presenting new findings regarding the use of Quantitative MRI for Prostate Cancer Detection and Monitoring at this year’s Radiological Society of North America (RSNA) conference in Chicago. The presentation by Dr. Tyler Seibert MD, PhD will take place on Wednesday, December 1, 2021 at 2 p.m. in the AI Theater of the McCormick Place Convention Center. 

Tyler Seibert MD, PhD is a board-certified radiation oncologist, clinical translational researcher at UC San Diego, and one of Cortechs.ai’s Medical Advisory Board members. Seibert is experienced in complex data analysis, including development, validation, and translation of novel methods in both biomedical imaging and genetics. Innovations like OnQ Prostate are navigating cancer detection with data and precision that benefits physicians like Seibert with their analysis capabilities.

My top priority is to improve precision diagnosis and treatment of prostate cancer through quantitative imaging,” said Dr Seibert, “Together with our partners, Cortechs.ai has the ability to impart real innovation in the oncology MRI field.”

OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. The software leverages an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), powered by AI, to enable faster, more accurate identification of restricted diffusion. Cortechs.ai will be stationed at booth 4542 showcasing and demonstrating NeuroQuant, NeuroQuant MS, OnQ Prostate. In addition, OnQ Neuro, a recently FDA cleared device for automated brain tumor segmentation with RSI technology, will also be introduced. Schedule a meeting in advance with a clinical specialist or account manager by clicking here

To learn more about Cortech.ai at RSNA 2021, visit www.cortechs.ai/rsna. Fellow AI-powered partner Subtle Medical, a healthcare technology company with deep learning solutions will be close-by at booth 4538 and you can request a meeting here. Cortechs.ai and Subtle Medical are a powerful team that contributes to real, fast, and objective results with imaging software. Together, our technology drastically reduces scan time and analysis.

About Cortechs.ai

Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions and prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.

Insights

19 December 2024

Elevating Neurological CT Precision and Efficiency

Learn how this powerful tool improves measurement accuracy, clinical confidence, and patient outcomes by streamlining workflows.

19 December 2024

OnQ Prostate: Advancing Prostate Cancer Imaging with OnQ Prostate

Discover how this advanced technology enhances diagnostic accuracy, reduces variability, and supports more informed clinical decisions.

19 December 2024

NeuroQuant Brain Tumor – Advancing Tumor Quantification in Clinical Practice

Discover how NeuroQuant® Brain Tumor can streamline tumor quantification, reduce manual workload, and support more precise decision-making.
Scroll to Top